

Mifepristone

This policy statement was developed by the Executive Committee of the Society of Obstetricians and Gynaecologists of Canada (SOGC) and approved by its Council.

The anti-progesterone steroid mifepristone has been developed, tested, and approved for use in several European countries and the United States. The use of such medication for terminating early pregnancy constitutes a significant medical and public health gain. The Society of Obstetricians and Gynaecologists of Canada (SOGC) supports a woman's right to choose safe abortion services. In

1991, the SOGC supported the introduction of mifepristone into Canada for clinical trials, and now supports its clinical use.

Therefore, the SOGC supports the approval and availability of mifepristone and other anti-progestins, as well as their appropriate prostaglandin counterparts, for appropriate research and clinical use in Canada. The SOGC urges Health Canada to work with professional organizations and industry to make this product available to women living in Canada.

J Obstet Gynaecol Can 2009;31(12):1180